Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Watt, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watt, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 39, 567-574, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

REVIEW, TUTORIAL

In-vitro sensitivities and treatment of less common mycobacteria

B Watt
Scottish Mycobacteria Reference Laboratory, City Hospital, Edinburgh, UK.

There are very few new agents available for the treatment of infections due to the less common mycobacteria. There have been very few systematic studies of in-vitro activity and fewer clinical trials. Yet such mycobacteria are an important cause of serious disease and often conventional antimycobacterial agents are unsuitable either because of in-vitro resistance of the pathogen concerned, or toxicity of one of the components of drug regimens. At present, newer macrolides and quinolones offer promise, but there is a need to extend the in-vitro studies already under way of newer agents against Mycobacterium avium and/or Mycobacterium tuberculosis, to the other, less common mycobacteria. The benzoxazinorifampicins, the oxazolidinones and the acridinones may prove to be of clinical value. In addition to more information on the in-vitro activity of newer agents, alone and in combination, based on systematic studies involving larger numbers of mycobacterial strains, we need clearer clinical information to enable therapeutic regimens to be formulated and validated. The British Thoracic Society study is but a first step. There need to be more.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Fernández-Roblas, J. Esteban, F. Cabria, J. C. López, M. S. Jiménez, and F. Soriano
In Vitro Susceptibilities of Rapidly Growing Mycobacteria to Telithromycin (HMR 3647) and Seven Other Antimicrobials
Antimicrob. Agents Chemother., January 1, 2000; 44(1): 181 - 182.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
S. Vacher, J. L. Pellegrin, F. Leblanc, J. Fourche, and J. Maugein
Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin
J. Antimicrob. Chemother., November 1, 1999; 44(5): 647 - 652.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.